Citadel Advisors
ACHL

Citadel Advisors’s Achilles Therapeutics ACHL Stock Holding History

Citadel Advisors’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,799
Closed -$18K – 15923
2024
Q4 		$18K Buy
+15,799
New +$16.3K ﹤0.01% 13243
2024
Q3 		– Sell
-61,391
Closed -$50K – 15499
2024
Q2 		$50K Sell
61,391
-43,602
-42% -$38.3K ﹤0.01% 11759
2024
Q1 		$131K Sell
104,993
-3,461
-3% -$3.73K ﹤0.01% 10963
2023
Q4 		$96.4K Buy
108,454
+50,828
+88% +$43.6K ﹤0.01% 10977
2023
Q3 		$52.4K Sell
57,626
-9,217
-14% -$8.77K ﹤0.01% 11705
2023
Q2 		$63.2K Sell
66,843
-403
-0.6% -$383 ﹤0.01% 11530
2023
Q1 		$64.4K Buy
67,246
+42,252
+169% +$45.8K ﹤0.01% 11836
2022
Q4 		$22.5K Buy
+24,994
New +$42.1K ﹤0.01% 13047
2022
Q3 		– Sell
-27,468
Closed -$69K – 13815
2022
Q2 		$69K Buy
27,468
+9,456
+52% +$23.3K ﹤0.01% 11722
2022
Q1 		$53K Sell
18,012
-38,545
-68% -$137K ﹤0.01% 12756
2021
Q4 		$283K Buy
+56,557
New +$342K ﹤0.01% 11052
2021
Q2 		– Sell
-39,253
Closed -$650K – 14598
2021
Q1 		$650K Buy
+39,253
New +$650K ﹤0.01% 9114

Other funds holding ACHL

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BAM
Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Citadel Advisors's ACHL Position: Q1 2025 in Review

Citadel Advisors sold out of Achilles Therapeutics (ACHL) in Q1 2025, closing a stake of 15,799 shares — an estimated $18K sold.

Citadel Advisors first reported a position in ACHL in Q1 2021 and held it in 12 quarters. The position peaked at $650K in Q1 2021. 6 funds tracked by Wall St. Rank hold ACHL as of Q1 2025.

  • Citadel Advisors reported no remaining Achilles Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Citadel Advisors sold 15,799 Achilles Therapeutics shares in Q1 2025, an estimated $18K.
  • Citadel Advisors first reported a position in Achilles Therapeutics in Q1 2021 and held it in 12 quarters.
  • Citadel Advisors's Achilles Therapeutics position peaked at $650K in Q1 2021.
  • 6 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.